News & Updates

Show Multimedia Only

Sustained benefits with ocrelizumab in relapsing-remitting MS

19 May 2022 by

Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.

Sustained benefits with ocrelizumab in relapsing-remitting MS

19 May 2022

High triglycerides-to-HDL-C ratio poses elevated stroke risk in people with healthy BMI

19 May 2022

Increased triglycerides (TG)-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) appears to be associated with a markedly raised risk of stroke only among individuals with healthy body mass index (BMI), according to a study.

High triglycerides-to-HDL-C ratio poses elevated stroke risk in people with healthy BMI

19 May 2022

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia

19 May 2022 by

Patients with Parkinson’s disease dementia (PDD) who continued treatment with pimavanserin had a lower risk of psychosis relapse compared with those on placebo, according to a post hoc analysis of the HARMONY* trial presented at AAN 2022.

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia

19 May 2022

Post-TAVR SLT risk does not differ with edoxaban or DAPT

16 May 2022 by

The risk of subclinical valve leaflet thrombosis (SLT) following transcatheter aortic valve replacement (TAVR) did not differ regardless of whether patients received edoxaban or dual antiplatelet therapy (DAPT) post-surgery, according to results of the ADAPT-TAVR* trial.

Post-TAVR SLT risk does not differ with edoxaban or DAPT

16 May 2022

No apparent link between COVID-19 vax and cerebrovascular outcomes

13 May 2022 by

Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.

No apparent link between COVID-19 vax and cerebrovascular outcomes

13 May 2022

Repeated diazepam nasal spray safe in kids, teens with seizures

13 May 2022

A long-term safety analysis of repeated diazepam nasal sprays finds acceptable rates of treatment-emergent adverse events in children and adolescents, with such side effects being comparably common between the two age groups.

Repeated diazepam nasal spray safe in kids, teens with seizures

13 May 2022

How does IV edaravone fare for ALS in the real world?

10 May 2022 by

Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.

How does IV edaravone fare for ALS in the real world?

10 May 2022

Early neurosurgery tied to better survival in spontaneous haemorrhagic stroke

09 May 2022

Neurosurgery performed 2–4 hours after presenting to the emergency department (ED) seems to result in better survival outcomes in patients with spontaneous haemorrhagic stroke, reports a recent study.

Early neurosurgery tied to better survival in spontaneous haemorrhagic stroke

09 May 2022

Ravulizumab shows rapid, sustained benefits for myasthenia gravis

09 May 2022 by

Treatment with ravulizumab leads to rapid and sustained reductions in myasthenia gravis (MG) symptoms, according to the CHAMPION study presented at AAN 2022.

Ravulizumab shows rapid, sustained benefits for myasthenia gravis

09 May 2022

AChEIs and memantine cost-effective, offer improvements in AD

09 May 2022 by

A systematic review and meta-analysis of Alzheimer’s disease (AD) therapies’ cost-effectiveness carried out by researchers from the Chinese University of Hong Kong (CUHK) identifies acetylcholinesterase inhibitors (AChEIs) and memantine as cost-effective and offering improvements in dementia-related symptoms.

AChEIs and memantine cost-effective, offer improvements in AD

09 May 2022

News & Updates

Showing Neurology articles

Showing

Specialty:

Sustained benefits with ocrelizumab in relapsing-remitting MS

Sustained benefits with ocrelizumab in relapsing-remitting MS

High triglycerides-to-HDL-C ratio poses elevated stroke risk in people with healthy BMI

High triglycerides-to-HDL-C ratio poses elevated stroke risk in people with healthy BMI

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia

Post-TAVR SLT risk does not differ with edoxaban or DAPT

Post-TAVR SLT risk does not differ with edoxaban or DAPT

No apparent link between COVID-19 vax and cerebrovascular outcomes

No apparent link between COVID-19 vax and cerebrovascular outcomes

Repeated diazepam nasal spray safe in kids, teens with seizures

Repeated diazepam nasal spray safe in kids, teens with seizures

How does IV edaravone fare for ALS in the real world?

How does IV edaravone fare for ALS in the real world?

Early neurosurgery tied to better survival in spontaneous haemorrhagic stroke

Early neurosurgery tied to better survival in spontaneous haemorrhagic stroke

Ravulizumab shows rapid, sustained benefits for myasthenia gravis

Ravulizumab shows rapid, sustained benefits for myasthenia gravis

AChEIs and memantine cost-effective, offer improvements in AD

AChEIs and memantine cost-effective, offer improvements in AD